The FDA cannot confirm that Fresenius Medical Care has complied with its directives to warn and educate dialysis clinics about the risks associated with GranuFlo and NaturaLyte.
Without confirmation that Fresenius has complied with the FDA’s directives, there is no way of knowing if individual clinics are still improperly dosing patients with these products. Patients could be at risk.
Individuals that suffered heart issues or strokes during or shortly after a dialysis treatment have a right to know what clinics administered GranuFlo and NaturaLyte. And patients receiving ongoing treatments need to know which dialysis clinics may still be using GranuFlo and NaturaLyte.
According to an FDA compliance representative, however, the agency does not have a list of clinics that used GranuFlo and NaturaLyte. This, of course, begs the question: How will the FDA know if Fresenius has complied with its directives? Are we to expect Fresenius to police itself when it has every reason to bury this story? Recall this is a company with a history of repeatedly violating federal and state law.
To make matters worse, many dialysis patients received GranuFlo and NaturaLyte without their knowledge. The only way to know for sure if you or a loved one were a victim of Fresenius’ wrongdoing is to have a qualified attorney review the medical history. Don’t simply take a clinic’s word for it. Click here to contact the GranuFlo and NaturaLyte lawyers at Upton Law Firm.
